EUCTR2017-001862-56-DE进行中（未招募）1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected with Respiratory Syncytial Virus - PLUM
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female infants and children =28 days to =36 months of age, defined at the time of randomization.
- •Subjects hospitalized (or in ER) at the time of randomization and unlikely to be discharged for the first 24 hours after randomization.
- •Subjects diagnosed with RSV infection using a PCR-based molecular diagnostic assay, with or without coinfection with another respiratory pathogen (respiratory virus or bacteria).
- •Subjects who have an acute respiratory illness with signs and symptoms consistent with a viral infection (eg, fever, cough, nasal congestion, runny nose, sore throat, myalgia, lethargy, shortness of breath, or wheezing) with onset =5 days from the anticipated time of randomization.
- •With the exception of the symptoms related to the RSV infection or defined comorbid condition for severe RSV disease (prematurity at birth [subject’s gestational age was <37 weeks; for infants <1 year old at randomization], bronchopulmonary dysplasia,congenital heart disease, other congenital diseases, Down syndrome, neuromuscular impairment, or cystic fibrosis), subjects must be medically stable on the basis of physical examination, medical history, vital signs/SpO2, and ECG performed at screening.
- •The subject’s estimated glomerular filtration rate (eGFR) is not below the lower limit of normal for the subject’s age (Schwartz equation calculation).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 180
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who are not expected to survive for more than 48 hours.
- •Subjects who have had major thoracic or abdominal surgery in the 6 weeks prior to randomization.
- •Subjects who received (within 12 months prior to screening) or who are currently on a waiting list for a bone marrow, stem cell, or solid organ transplant, who received radiation or chemotherapy, or who are currently taking immunosuppressive medication.
- •Subjects who have a known or suspected immunodeficiency (except immunoglobulin A [IgA] deficiency), such as a known human immunodeficiency virus infection.
- •Subjects who have a history of or concurrent illness (beyond a defined comorbid condition for severe RSV disease) that in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject, or that could prevent, limit, or confound the protocol-specified assessments.
- •Subjects aged =28 days to 35 days with <8.0 g/dL (Grade 3) hemoglobin or a cardiac failure secondary to anemia (Grade 4) and subjects aged =36 days to 36 months with <7.0 g/dL (Grade 3) hemoglobin or cardiac failure secondary to anemia (Grade 4).
- •Subjects aged =28 days to 60 days with <899/mm3 absolute neutrophil count) and subjects aged =61 days to =36 months with <399/mm3 absolute neutrophil count.
- •Subjects aged =28 days to =36 months with <49,999/mm3 platelet count (Grade 3/4).
研究者
相似试验
进行中（未招募）
不适用
A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial CystitisBladder Pain Syndrome / Interstitial CystitisMedDRA version: 14.1Level: LLTClassification code 10071166Term: Bladder pain syndromeSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008928Term: Chronic interstitial cystitis NOSSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008927Term: Chronic interstitial cystitisSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: PTClassification code 10011796Term: Cystitis interstitialSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-004555-39-NLAstellas Pharma Europe B.V.300
进行中（未招募）
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A InfectioEUCTR2015-003002-17-BEJanssen-Cilag International NV90
进行中（未招募）
1 期
A study to investigate how safe and able to produce an effect in the body study drug VX-150 is in patients with pain that typically begins in the feet or handPain Caused by Small Fiber NeuropathyMedDRA version: 20.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.1Level: PTClassification code 10073928Term: Small fibre neuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-001042-10-ITVERTEX PHARMACEUTICALS INCORPORATED89
进行中（未招募）
1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensioEUCTR2008-007455-26-BEGilead Sciences, Inc.160
尚未招募
2 期
A study to calculate efficacy and safety of SAR441566 in adults with rheumatoid arthritisCTRI/2024/05/067017Sanofi Healthcare India Pvt Limited (SHIPL)